Synonyms: IY-5511 | IY5511 | IY5511HCl | KB-146009 | Supect®
radotinib is an approved drug (South Korea (2012))
Compound class:
Synthetic organic
Comment: This drug is approved only in South Korea, for the treatment of chronic myeloid leukemia (CML), where its trade name is Supect.
It is Example 5 in patent US7501424 [1]. The marketed formulation contains the hydrochloride salt.. View more information in the IUPHAR Pharmacology Education Project: radotinib |
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (South Korea (2012)) |
IUPAC Name |
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide |
International Nonproprietary Names | |
INN number | INN |
9242 | radotinib |
Synonyms |
IY-5511 | IY5511 | IY5511HCl | KB-146009 | Supect® |
Database Links | |
CAS Registry No. | 926037-48-1 |
DrugCentral Ligand | 5188 |
GtoPdb PubChem SID | 223366145 |
PubChem CID | 16063245 |
Search Google for chemical match using the InChIKey | DUPWHXBITIZIKZ-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | DUPWHXBITIZIKZ |
Search PubMed clinical trials | radotinib |
Search PubMed titles | radotinib |
Search PubMed titles/abstracts | radotinib |
UniChem Compound Search for chemical match using the InChIKey | DUPWHXBITIZIKZ-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | DUPWHXBITIZIKZ-UHFFFAOYSA-N |
Wikipedia | Radotinib |